-K C Anderson Researcher Activity Profile

Research Author Detailed Information 

K C Anderson Publication Rate By Year

K C Anderson has published 2 paper(s) in 2001, 1 paper(s) in 2002, 1 paper(s) in 2005, 10 paper(s) in 2006, 55 paper(s) in 2007, 11 paper(s) in 2008, for a total of 80 research publications in total.

K C Kc Anderson Author Information

LAST NAME: anderson

FIRST NAME: K C

INITIALS: kc

AFFILIATION:

Papers

K C Anderson's Publication Record

1. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Year Published: 2007
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
2. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, and Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA. ruben_carrasco@dfci.harvard.edu
3. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. Year Published: 2001
Department of Adult Oncology, Dana Farber Cancer Institute,Boston Massachusetts 02115, USA.
4. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Year Published: 2006
Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA.
5. The promise of extinction research for the prevention and treatment of anxiety disorders. Year Published: 2006
6. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Year Published: 2006
Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, The Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA.
7. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Year Published: 2006
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. Constantine_Mitsiades@dfci.harvard.edu
8. Recent advances in the treatment of Multiple Myeloma. Year Published: 2006
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
9. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Year Published: 2006
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.
10. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Year Published: 2006
Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA. paul_richardson@dfci.harvard.edu
11. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Year Published: 2006
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. klaus.podar@dfci.harvard.edu
12. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Year Published: 2007
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
13. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. klaus_podar@dfci.harvard.edu
14. Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway. Year Published: 2007
Jerome Lipper Multiple-Myeloma Center, Department of Medical-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
15. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Year Published: 2007
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA. Kenneth_anderson@dfci.harvard.edu
16. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA. kenneth_anderson@dfci.harvard.edu
17. Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass., USA. laurence.catley@mater.org.au
18. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
19. Inhibition of the TGF-beta signaling pathway in tumor cells. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA.
20. Body mass index, physical activity, and risk of multiple myeloma. Year Published: 2007
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA. brenda.birmann@channing.harvard.edu
21. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Year Published: 2007
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. yu-tzu_tai@dfci.harvard.edu
22. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
23. Year Published: 2007
24. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Year Published: 2007
Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
25. Novel therapies in myeloma. Year Published: 2007
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.
26. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Year Published: 2007
Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
27. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Year Published: 2007
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. rajks@mayo.edu
28. Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Year Published: 2007
29. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Year Published: 2007
Dana-Farber Cancer Institute, Boston, MA 02115, USA. paul_richardson@dfci.harvard.edu
30. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Year Published: 2007
Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
31. Preface. Year Published: 2007
Jerome Lipper Multiple Myeloma Cente, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
32. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Year Published: 2007
Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
33. Mouse models of human myeloma. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
34. Preclinical studies of novel targeted therapies. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
35. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
36. Targeted treatments to improve stem cell outcome: old and new drugs. Year Published: 2007
1Department of Medical Oncology, The Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
37. The evolving background for high-dose treatment for myeloma. Year Published: 2007
1Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK.
38. Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Year Published: 2005
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA, USA. Constantine_Mitsiades@dfci.harvard.edu
39. Lenalidomide in multiple myeloma. Year Published: 2006
Jerome Lipper Multiple Myeloma Center, Divison of Hematologic Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. paul_richardson@dfci.harvard.edu
40. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Year Published: 2006
Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA. nraje@partners.org
41. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Year Published: 2007
Dana-Farber Cancer Institute, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA. klaus_podar@dfci.harvard.edu
42. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Year Published: 2007
43. Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Year Published: 2007
44. The malignant clone and the bone-marrow environment. Year Published: 2007
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
45. From the bench to the bedside: emerging new treatments in multiple myeloma. Year Published: 2007
Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA.
46. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Year Published: 2007
Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
47. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Year Published: 2007
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. rajks@mayo.edu
48. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Year Published: 2007
Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. constantine_mitsiades@dfci.harvard.edu
49. Mouse models of human myeloma. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. constantine_mitsiades@dfci.harvard.edu
50. Preclinical studies of novel targeted therapies. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. teru_hideshima@dfci.harvard.edu
51. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
52. [In Process Citation] Year Published: 2008
53. Targeted treatments to improve stem cell outcome: old and new drugs. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
54. The evolving background for high-dose treatment for myeloma. Year Published: 2007
Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK.
55. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Year Published: 2007
Dana-Farber Cancer Institute, Boston, MA 02115, USA. paul_richardson@dfci.harvard.edu
56. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Year Published: 2007
Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
57. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Year Published: 2008
Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
58. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Year Published: 2007
Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
59. Multiple myeloma. Preface. Year Published: 2007
Jerome Lipper Multiple Myeloma Cente, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
60. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Year Published: 2007
Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. constantine_mitsiades@dfci.harvard.edu
61. Mouse models of human myeloma. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. constantine_mitsiades@dfci.harvard.edu
62. Preclinical studies of novel targeted therapies. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. teru_hideshima@dfci.harvard.edu
63. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
64. Novel therapies in myeloma. Year Published: 2007
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.
65. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Year Published: 2008
66. Targeted treatments to improve stem cell outcome: old and new drugs. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
67. The evolving background for high-dose treatment for myeloma. Year Published: 2007
Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK.
68. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Year Published: 2008
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 022115, USA. klaus_podar@dfci.harvard.edu
69. Targeting akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Year Published: 2008
Authors' Affiliations: James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.
70. Multiple myeloma. Year Published: 2001
Clinical Investigations, H. Lee moffitt Cancer Center, Tampa, FL 33612-9497, USA.
71. Multiple myeloma. Year Published: 2002
Dana-Farber Cancer Institute, Boston, MA 02115, USA.
72. Inhibition of the TGF-beta signaling pathway in tumor cells. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA.
73. Clinically relevant end points and new drug approvals for myeloma. Year Published: 2008
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. kenneth_anderson@dfci.harvard.edu
74. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Year Published: 2008
Division of Hematology, University of Turin, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy. appalumbo@yahoo.com
75. The malignant clone and the bone-marrow environment. Year Published: 2007
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. klaus_podar@dfci.harvard.edu
76. From the bench to the bedside: emerging new treatments in multiple myeloma. Year Published: 2007
Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA.
77. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Year Published: 2008
The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Myeloma Research, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. dharminder_chauhan@dfci.harvard.edu
78. Clinically relevant end points and new drug approvals for myeloma. Year Published: 2008
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. kenneth_anderson@dfci.harvard.edu
79. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Year Published: 2008
Division of Hematology, University of Turin, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy. appalumbo@yahoo.com
80. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. Year Published: 2008
Center for Regenerative Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.